StockData
Rezolute, Inc. logo

Rezolute, Inc. (RZLT) company profile

RZLTNasdaqPharmaceutical PreparationsFiscal year ends June 30
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$4.25+0.24 (+5.85%)

Close on Nov 18, 2026Market cap $411.07MP/E –Yield –

About Rezolute

Pharmaceutical Preparations, SIC 2834

Rezolute, Inc. is a late-stage rare disease biopharmaceutical company focused on developing therapies for refractory and debilitating hypoglycemia associated with forms of hyperinsulinism. The company's principal clinical asset is ersodetug, an intravenously administered human monoclonal antibody designed to down-modulate insulin receptor activity and normalize blood glucose levels. Its pipeline targets conditions such as congenital hyperinsulinism in pediatric patients and tumor hyperinsulinism caused by neuroendocrine islet cell tumors and non-islet cell tumors. Potential end users and target recipients include pediatric individuals suffering from congenital hyperinsulinism, as well as hospitalized or adult patients with inoperable or metastatic tumors experiencing severe hypoglycemia.

The company operates in the United States and has conducted multinational clinical studies for its therapeutic programs. Rezolute maintains an executive office and headquarters located in Redwood City, California, and employed 58 full-time staff members based entirely in the United States as of June 30, 2026.

Summary of the business section of Rezolute's latest annual report, written by StockData.

Company profile

Company

Legal name
Rezolute, Inc.
Founded
2010
Headquarters
Redwood City, CA
Address
275 Shoreline Drive, Suite 500 94065
Phone
(650) 206-4507
Employees
58, Jun 30, 2026
Industry
Pharmaceutical Preparations
Incorporated in
Nevada
Fiscal year ends
June 30
Auditor
GRANT THORNTON LLP, Newport Beach, California

Stock & identifiers

Ticker
RZLT
Former tickers
ANTB until Feb 14, 2018; FMYY until May 15, 2013
Exchange
Nasdaq
IPO date
Jan 14, 2013
Shares outstanding
97M, Sep 21, 2026
Public float
$203.92M, Dec 31, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-50 reverse, Oct 13, 2020; 1-for-6 reverse, May 1, 2014
SEC CIK
1509261
CUSIP
76200L309
ISIN
US76200L3096
FIGI
BBG001XWWHL4
Share class FIGI
BBG001XWWJC0
LEI
549300T05L48T72P2G08
EIN
27-3440894

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Nevan C. ElamCEO, Director605,497
Daron EvansCFO477,400
Sunil Ratilal KarnawatChief Commercial Officer79,173
Brian Kenneth RobertsChief Medical Officer309,351
Wladimir HogenhuisDirector119,675
Philippe FauchetDirector55,500
Nerissa KreherDirector58,576
Gil M. LabrucherieDirector109,072
Young-Jin KimDirector8,594,336
Erik HarrisDirector21,000

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2026$5.71M$4.09M$2.49M$263–
FY2025$2.85M$2.10M$1.58M$225–
FY2024$1.19M$4.96M$601.01K$217–
FY2023$973.65K-$1.96M$738.86K$14–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2026

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsOtherTotalvs. prior year
Nevan Charles Elam
Chief Executive Officer
$655.00K$450.91K$3.22M$1.36M$25.81K$5.71M+100%
Brian Roberts
Chief Medical Officer
$512.16K$226.83K$1.25M$526.05K$50.23K$2.56M+79%
Daron Evans
Chief Financial and Business Officer
$480.00K$242.67K$1.09M$460.30K$15.38K$2.29M+33%
Sunil Karnawat
Chief Commercial Officer
$415.63K$237.30K$488.87K$1.46M$25.88K$2.62M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of June 30, 2026, we had 58 full-time employees, of which 40 employees were engaged in research and development and 18 employees were engaged in general and administrative functions.”

Corporate history

Events identified from SEC filings

DateEventDetails
Mar 14, 2024Auditor changeChange in certifying accountant (8-K Item 4.01)
Nov 22, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 8, 2021Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 28, 2020Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 4, 2020ListingRegistration of securities on an exchange (Form 8-A)
Sep 29, 2020Late filingNotification of late filing
Oct 16, 2018Auditor changeChange in certifying accountant (8-K Item 4.01)
Oct 1, 2018Late filingNotification of late filing
Dec 7, 2017Name changeName changed from AntriaBio, Inc. to Rezolute, Inc.
Nov 10, 2014Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 30, 2014Late filingNotification of late filing
Feb 22, 2013Auditor changeChange in certifying accountant (8-K Item 4.01)
Feb 14, 2013Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Feb 6, 2013Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jan 11, 2013Name changeName changed from FITS MY STYLE INC to AntriaBio, Inc.
Nov 14, 2012Late filingNotification of late filing
Oct 1, 2012Late filingNotification of late filing

See a number that looks wrong?